Kiniksa Pharmaceuticals International, plc (KNSA)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenue | 156,797 | 112,214 | 108,631 | |
| Selling, general and administrative | 46,863 | 46,399 | 42,395 | |
| Research and development | 18,753 | 26,057 | 24,017 | |
| Cost of goods sold | 18,603 | 20,109 | 12,322 | |
| Collaboration expenses | 52,418 | 29,307 | 30,014 | |
| Total operating expenses | 136,637 | 121,872 | 108,748 | |
| Income (loss) from operations | 20,160 | -9,658 | -117 | |
| Other income | 2,717 | 2,457 | 2,421 | |
| Income (loss) before income taxes | 22,877 | -7,201 | 2,304 | |
| Provision for income taxes | 5,045 | 5,492 | 6,212 | |
| Net income (loss) | 17,832 | -12,693 | -3,908 | |
| Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax | 112 | 89 | - | |
| Total other comprehensive income (loss) | 112 | 89 | - | |
| Total comprehensive income (loss) | 17,944 | -12,604 | -3,908 | |
| Earnings per share, basic | 0.24 | -0.18 | -0.06 | |
| Earnings per share, diluted | 0.23 | -0.18 | -0.06 | |
| Weighted average number of shares outstanding, basic | 73,438,530 | 71,726,685 | 71,004,640 | |
| Weighted average number of shares outstanding, diluted | 77,942,082 | 71,726,685 | 71,004,640 | |